<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27063585</identifier>
<setSpec>1988-3013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Mut, Alejandro</dc:author>
<dc:author>Díez-Presa, Lorena</dc:author>
<dc:author>Samper, Josefa</dc:author>
<dc:author>Arribas, Leoncio</dc:author>
<dc:author>Santamaría, Paula</dc:author>
<dc:author>Tortajada, María Isabel</dc:author>
<dc:author>Vendrell, Juan Bosco</dc:author>
<dc:author>Guinot, José Luis</dc:author>
<dc:author>Santos, Miguel Ángel</dc:author>
<dc:description xml:lang="en">INTRODUCTION AND GOALS To analyze the results obtained after treatment of early stage (T1-T2) squamous cell carcinoma of the lip with high dose rate brachytherapy and evaluate the efficacy of this treatment in both local and regional control. MATERIALS AND METHODS Retrospective analysis of the treatments performed at our department from March 1999 to March 2013 with high dose rate brachytherapy with rigid needles. We included 68 patients, 63 men and 5 women; 37 patients (54.4%) presented a T1 tumour, less than or equal to 2cm, while the other 31 (45.6%) were classified as T2. Median total dose was 45Gy, with a median dose per fraction of 5Gy x 9 fractions twice a day for 5 days. RESULTS With a mean follow-up of 56.4 months, local control was 96.9%. Stratifying by tumour size, local control of T1 cases was 100%, while T2 achieved 93.2% (2 local recurrences). Regional control at 5 years was 93.8% for T1, and 80.8% for T2. In 11 cases with elective cervical treatment, no regional failure happened. As for toxicity, no patient presented soft tissue, or bone, necrosis. All patients achieved good or excellent cosmetic and functional results. CONCLUSIONS High dose rate brachytherapy allows effective, safe treatments for squamous cell carcinoma of the lip, with good aesthetic and functional results. It can be considered a valid alternative for surgery in early stage tumours.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Alta tasa de dosis</dc:subject>
<dc:subject>Lip</dc:subject>
<dc:subject>Carcinoma</dc:subject>
<dc:subject>Squamous cell</dc:subject>
<dc:subject>Brachytherapy</dc:subject>
<dc:subject>Braquiterapia</dc:subject>
<dc:subject>Labio</dc:subject>
<dc:date>2016 Sep-Oct </dc:date>
<dc:title xml:lang="es">Braquiterapia de alta tasa en el carcinoma escamoso de labio en estadios iniciales.</dc:title>
<dc:title xml:lang="en">High dose rate brachytherapy in early stage squamous-cell carcinoma of the lip.</dc:title>
<dc:publisher>Acta otorrinolaringologica espanola</dc:publisher>
</metadata>
</record>
</pubmed-document>
